Open Orphan, Salt Lake Potash, Cadence Minerals & Paul Hill
Justin Waite
Vox Markets Podcast with Justin Waite
12:37, 4th May 2020

AudioBoom Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here:

On today's Vox Markets Podcast: Open Orphan, Salt Lake Potash, Cadence Minerals & Paul Hill

Cathal Friel, Executive Chairman of Open Orphan (ORPH) talks about the major new contract they've signed with a US biotechnology company.

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services.

Tony Swiericzuk CEO of Salt Lake Potash (SO4) FOLLOW covers some of the highlights from its quarterly report including the completion of their Lake Way Village.

Salt Lake Potash plans to build the most sustainable, most rewarding fertiliser project in the world by developing organic Sulphate of Potash (SOP) from the Goldfields Salt Lakes which are nine lakes totalling over 3,300km² of playa surface ideal for trench extractions in Western Australia.

(Interview starts at 10 minutes 22 seconds)

Kiran Morzaria CEO of Cadence Minerals (KDNC) FOLLOW provides an update on operations at their Amapá project.

Cadence is a global investor and cornerstone partner in the discovery and development of lithium and iron ore deposits that will fuel our greener tomorrow.

(Interview starts at 24 minutes 40 seconds)

Paul Hill, full time investor and equity analyst give his view on the market and what he's been buying and selling.

(Interview starts at 34 minutes 39 seconds)  

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles